- The biotech company is testing a drug called rosnilimab in patients with rheumatoid arthritis and ulcerative colitis. Both are inflammatory conditions.
In the study called Renoir, patients showed statistically significant improvements across numerous measures. Importantly, after 12 weeks of treatment, 36% to 47% of patients showed at least a 50% improvement in symptoms of rheumatoid arthritis. Nearly seven in 10 patients — 69% — reached a low-disease activity score on another measure after 14 weeks.
These surpass historical benchmarks, Wedbush analyst Martin Fan said in a client report. He also noted the company is now planning to have the results of a study of rosnilimab in patients with ulcerative colitis in the fourth quarter of 2025 vs. earlier forecasts for the first quarter of 2026.
AnaptysBio Mets Primary Goal
The primary goal of the study was to show low levels of C-reactive protein after 12 weeks. C-reactive protein in the blood indicates there's inflammation somewhere in the body. Patients who received rosnilimab showed statistically significant improvement in C-reactive protein levels vs. the placebo group.
After 14 weeks, patients showed the best-ever improvements on scales called ACR20, ACR50 and ACR70. This means their symptoms improved by 20%, 50% and 70%. In the first group, 79% to 82% of overall patients showed improvement. More than half — 59% to 67% — reached at least a 50% symptom improvement. And 41% to 48% of patients had at least a 70% improvement in symptoms.
Notably, 68% to 71% of patients reached a low-disease activity score on another scale measuring symptoms.
No comments:
Post a Comment